Investment Rating - The report maintains a positive outlook on Geely Automobile, indicating a strong performance in sales and profitability, with a target sales volume of 3.45 million units for 2026, driven by successful high-end brands and the Silver River product line [3][4]. Core Insights - Geely's sales reached a record 3.02 million units in 2025, representing a 39% year-on-year increase, with an adjusted net profit of 14.4 billion yuan, aligning with market expectations [3]. - The company is expected to enhance its product lineup in 2026, focusing on smart driving features and expanding its offerings to better compete in the market [6]. - Geely's revenue for Q4 2025 was 105.8 billion yuan, a 22% increase year-on-year, with a gross margin of 16.9% [4]. Summary by Relevant Sections Sales Performance - Geely's sales target for 2026 is set at 3.45 million units, with a significant contribution from high-end models like Zeekr and Lynk & Co, which are projected to increase their share from 19% in 2025 to 22% in 2026 [4]. - The Galaxy series and fuel vehicles are expected to account for approximately 42% and 36% of 2026 sales, respectively [4]. Profitability and Market Position - The report highlights Geely's competitive advantage in profitability compared to peers, with expectations of export growth and high-end market penetration offsetting cost inflation and local market weakness [3]. - The average revenue per vehicle remained stable at 123,800 yuan, benefiting from the increased share of high-end models [5]. Product Development and Innovation - Geely plans to enhance its product offerings by integrating advanced smart driving technologies and expanding its product range to include a new off-road SUV targeting competitors [6]. - The company aims to improve its product structure to mitigate the impact of rising raw material costs, with a focus on high-margin models [5]. Market Trends and Catalysts - Key catalysts for Geely's growth include the successful launch of new electric vehicle models, the accelerating penetration of electric vehicles in China, and advancements in vehicle smart technology [7].

Investment Rating - The report recommends a positive investment outlook for the company, highlighting its strategic transition towards a dual-platform model combining ICL and CRO services [22]. Core Insights - The company has demonstrated resilience in its revenue streams, with a notable 30% year-on-year growth in its co-construction business and an 18% increase in CRO revenue, despite an overall revenue decline of 13.3% due to industry adjustments [21]. - The strategic acquisition of Crown Bioscience for approximately $204 million is expected to enhance the company's capabilities in drug development and clinical research, marking a significant shift from a traditional medical diagnostics provider to a comprehensive laboratory service provider [3][11]. - The company is focusing on expanding its high-end testing services and enhancing operational efficiency through AI and lean management practices, which have already resulted in a 13% reduction in reagent procurement costs and an 11% increase in laboratory efficiency [21][18]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 1.27 billion RMB, a decrease of 13.3% year-on-year. However, the co-construction business saw a 30% increase in revenue, with a four-year compound annual growth rate (CAGR) of 48% [2][7]. - The CRO business also experienced an 18% revenue growth, with new contract values exceeding 24 million RMB [11]. Business Segments - The ICL segment remains a cornerstone of the company's operations, providing over 4,000 medical testing services across various disease areas, with a focus on infection, oncology, and hematology [4]. - The special testing segment is identified as a key growth driver, with a projected revenue growth of over 18% for 2024, particularly in oncology testing, which is expected to grow by 47% [5][6]. Strategic Initiatives - The company is enhancing its special testing capabilities through strategic partnerships and acquisitions, including the acquisition of Yuan De You Qin, a leading blood disease diagnostics company [6]. - The co-construction business model is evolving into a strategic partnership with hospitals, creating a robust service barrier and strong customer loyalty [7][8]. Market Outlook - The ICL market in China is projected to reach 51.3 billion RMB by 2026, with a CAGR of 18.2% from 2021 to 2026, driven by increasing outsourcing demands from hospitals [15]. - The CRO market is also expected to grow significantly, with forecasts indicating a market size of 528.6 billion RMB in China by 2026 [17]. Competitive Advantages - The company boasts a leading laboratory network and R&D capabilities, supported by advanced operational management and logistics systems, which create a strong competitive moat in the independent medical laboratory industry [18]. - The integration of AI in drug discovery and clinical research processes is enhancing operational efficiency and creating new commercial opportunities [13][19]. Future Plans - The company aims to transition from traditional ICL services to a comprehensive healthcare service platform, focusing on quality improvements and expanding its market share in high-end testing and CRO services [20].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 19.3, indicating a potential upside of 40.2% from the current price of HKD 13.78 [4][6]. Core Insights - The company has returned to a rapid growth trajectory with a revenue increase of 9.9% year-on-year to RMB 8.21 billion in 2025, driven by exclusive/brand products and innovative drugs, which saw a revenue increase of 23.3% to RMB 5.61 billion, accounting for 60% of total revenue [2][3]. - The company has achieved significant breakthroughs in innovation, with two new drugs approved for market and several others in various stages of development, enhancing its growth prospects [4][5]. Financial Summary - Revenue for 2025 is projected at RMB 8.21 billion, reflecting a 9.9% increase from the previous year, with a forecasted revenue growth of 23.2% in 2026 and 25.5% in 2027 [5][7]. - Adjusted net profit for 2025 is expected to be RMB 1.49 billion, down 8.1% year-on-year, but projected to rebound with a 29.8% increase in 2026 [5][7]. - The company has a dividend payout of RMB 660 million for 2025, with a payout ratio of 47.5% [2][5]. Product Development and Market Position - The company is focusing on stabilizing sales of older products while ramping up new product launches, including innovative treatments for skin conditions and other diseases, which are expected to contribute significantly to future revenues [3][4]. - The company is expanding its market presence in Southeast Asia and building an overseas platform to enhance its competitive position [4][6].

Investment Rating - The report assigns a positive investment rating to the company, highlighting its potential for value re-evaluation driven by its dual-platform strategy of "ICL + CRO" [3][22]. Core Insights - The company is transitioning from a leading medical diagnostics platform in China to a global integrated laboratory service provider, covering both diagnostic services and clinical development [4][22]. - The independent medical laboratory services (ICL) and contract research organization (CRO) segments are identified as key growth drivers, with significant revenue growth in both areas [12][22]. - The report emphasizes the company's strategic acquisitions and partnerships, particularly the acquisition of Crown Bioscience, which enhances its capabilities in drug development and clinical research [12][15][22]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved total revenue of 1.27 billion RMB, a year-on-year decline of 13.3%. However, the ICL business revenue grew by 30%, with a four-year compound annual growth rate (CAGR) of 48%, while CRO revenue increased by 18% [3][21]. - The gross profit was 454 million RMB, with a gross margin of 35.8%. Shareholder profit amounted to 27.27 million RMB, and cash and cash equivalents were approximately 750 million RMB [3]. Business Segments - The ICL segment is a cornerstone of the business, providing over 4,000 medical testing services across various disease areas, with a focus on infection, oncology, and hematology [5]. - The special testing (特检) business is a strategic growth engine, with a projected revenue growth of over 18% in 2024 and a five-year CAGR of 33%. The oncology testing line alone saw a growth of over 9% in the first half of 2025 [6][7]. - The CRO segment reported an 18% revenue increase in the first half of 2025, with new contracts rising from 93 to 111, and new contract values exceeding 24 million RMB [12]. Strategic Initiatives - The company is enhancing its special testing capabilities through strategic acquisitions and partnerships, including a significant collaboration with Guardant Health to support clinical drug development in oncology [7][8]. - The co-construction business model has shown remarkable growth, with a 30% year-on-year increase in revenue, driven by partnerships with major hospitals [8][9]. - The acquisition of Crown Bioscience is expected to extend the company's CRO business upstream in the drug development value chain, creating a comprehensive service loop from early drug discovery to clinical trials [15][22]. Market Outlook - The ICL market in China has a penetration rate of only 6%, indicating substantial growth potential, with an expected market size of 51.3 billion RMB by 2026 [16]. - The global and Chinese CRO markets are projected to grow significantly, with estimates of 33.25 billion USD and 52.86 billion RMB respectively by 2026 [17]. Competitive Advantages - The company boasts a leading laboratory network, operational efficiency, and advanced IT infrastructure, which collectively create a strong competitive moat in the independent medical laboratory industry [18]. - The integration of AI in drug discovery and clinical research enhances the company's operational capabilities and positions it favorably in the market [14][18]. - The strategic acquisition of Crown Bioscience is expected to create a unique "diagnostics + contract research" synergy, differentiating the company from traditional ICL or CRO firms [18][19]. Future Plans - The company's strategic focus is on transitioning to a comprehensive medical service platform, enhancing the quality of its co-construction business, and expanding its CRO services [20][22]. - The long-term goal is to increase the revenue share of the CRO business to match that of the ICL business, fostering deeper integration and sustainable growth [20].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 19.3, indicating a potential upside of 40.2% from the current price of HKD 13.78 [4][6]. Core Insights - The company has returned to a rapid growth trajectory with a revenue increase of 9.9% in 2025, reaching CNY 8.21 billion, driven by strong performance in exclusive/brand products and innovative drugs, which saw a revenue increase of 23.3% to CNY 5.61 billion, accounting for 60% of total revenue [2][3]. - The company has achieved significant breakthroughs in innovation, with two new drugs approved and several others in the pipeline, including treatments for vitiligo and psoriasis, which are expected to contribute to future revenue growth [3][4]. Financial Summary - In 2025, the company reported a revenue of CNY 8.21 billion, with a gross profit margin of 71.5%, a slight decrease of 1.1 percentage points from the previous year [2][5]. - The adjusted net profit for 2025 was CNY 1.78 billion, reflecting a 3.6% increase after accounting for a one-time tax adjustment [2][5]. - The company plans to distribute CNY 660 million in dividends, resulting in a payout ratio of 47.5% [2]. Revenue Breakdown - The revenue growth was driven by various segments: cardiovascular products increased by 2.4% to CNY 2.99 billion, digestive and autoimmune products grew by 3.3% to CNY 2.97 billion, skin health products surged by 73.2% to CNY 1.07 billion, and ophthalmology revenue rose by 12.9% to CNY 710 million [2][3]. Future Projections - The company anticipates a revenue increase of 23.2% in 2026, reaching CNY 10.12 billion, with continued growth expected in subsequent years [5][8]. - The introduction of new products, including innovative treatments for various conditions, is expected to significantly boost revenue, with peak sales projections for certain products reaching CNY 6 billion by 2030 [3][4].

Investment Rating - The report maintains a "Buy" rating for China Oriental Education with a target price of HKD 10.38 per share, indicating a potential upside of 73.3% from the current price of HKD 5.99 [7][15]. Core Insights - The company's performance is strong, with adjusted net profit at the upper limit of the earnings forecast. In 2025, revenue reached HKD 46.16 billion, a year-on-year increase of 12.1%, while net profit grew by 47.5% to HKD 7.56 billion. Adjusted net profit increased by 50.9% to HKD 7.92 billion [3][10]. - Growth is driven by an increase in training participants, higher average tuition fees, and continuous operational efficiency improvements. The company reported a 15% increase in overall enrollment, with significant growth in short-term training programs [10][12]. - All business segments showed growth, with the beauty industry maintaining a high growth rate of 71.7%. The average training participants and tuition fees also increased across various segments [11][12]. Financial Performance - In 2025, the company's gross margin was 55.3%, up 3.9 percentage points year-on-year, primarily due to revenue growth and cost efficiency. The net profit margin improved to 16.4%, reflecting a 3.9 percentage point increase [6][14]. - The company effectively managed its expenses, with sales, management, R&D, and financial expense ratios decreasing compared to the previous year [14]. - Forecasts for 2026-2028 predict revenue growth to HKD 53.27 billion, HKD 60.38 billion, and HKD 68.19 billion, with corresponding net profits of HKD 10.04 billion, HKD 12.57 billion, and HKD 14.83 billion, indicating robust growth prospects [8][15].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to see a long-term growth trajectory despite short-term fluctuations, with a focus on the recovery of its vaping business [1] - The company has demonstrated strong performance in its mature vaping business, with a notable recovery in overall performance [2] - The HNB (Heat-not-Burn) segment is experiencing significant growth, with a projected revenue increase of 476% year-on-year [3] - The emerging medical and beauty vaping business is in the exploratory phase, with high R&D investments impacting short-term performance but offering substantial long-term profit potential [3] - The company is expected to maintain a high dividend yield, reflecting confidence in future growth [4] Summary by Sections Financial Performance - In 2025, the company achieved a revenue of 14.3 billion HKD, a year-on-year increase of 21%, while the net profit attributable to shareholders was 1.06 billion HKD, a decrease of 19% [1] - The adjusted net profit for 2025 was 1.53 billion HKD, reflecting a year-on-year increase of 1.3% [1] - The company plans to distribute a dividend of 0.2 HKD per share for 2025 [1] Business Segments - The vaping business in the US and Europe showed revenue growth of 19% and 2% respectively, while the Chinese market saw a decline of 11% [2] - The company's own brand generated revenue of 2.9 billion HKD, with significant growth in the US and European markets [2] - The HNB segment generated 1.3 billion HKD in revenue, with plans for expansion into key markets like Japan and Poland [3] - The medical and beauty vaping segment is preparing for FDA approval and aims to build small-scale production capabilities [3] Future Projections - Revenue projections for 2026-2028 are 16.91 billion HKD, 19.98 billion HKD, and 23.66 billion HKD, with year-on-year growth rates of 18.64%, 18.13%, and 18.42% respectively [4] - Net profit projections for the same period are 1.65 billion HKD, 2.57 billion HKD, and 3.49 billion HKD, with growth rates of 55.20%, 55.58%, and 35.69% respectively [4] - The expected EPS for 2025-2027 is 0.27 HKD, 0.41 HKD, and 0.56 HKD, with corresponding P/E ratios of 42, 27, and 20 times [4]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 10.38 per share, indicating a potential upside of 73.3% from the current price of HKD 5.99 [7][15]. Core Insights - The company has demonstrated strong performance with adjusted net profit at the upper limit of earnings forecasts, achieving a revenue of HKD 46.16 billion in 2025, a year-on-year increase of 12.1%, and a net profit of HKD 7.56 billion, up 47.5% year-on-year [3][10]. - The growth in performance is attributed to an increase in training participants, higher average tuition fees, and continuous operational efficiency improvements [10][11]. - All business segments have shown growth, with the beauty industry maintaining a high growth rate, particularly benefiting from a significant increase in training participants [11][12]. Financial Performance - In 2025, the company achieved a gross profit margin of 55.3%, an increase of 3.9 percentage points year-on-year, driven by revenue growth and cost efficiency [6][13]. - The company’s sales, management, R&D, and financial expense ratios have decreased, indicating effective cost control [14]. - The adjusted net profit margin for 2025 was 17.2%, reflecting a year-on-year increase of 4.3 percentage points [14]. Future Projections - The company is expected to achieve revenues of HKD 53.27 billion, HKD 60.38 billion, and HKD 68.19 billion for the years 2026 to 2028, representing year-on-year growth rates of 15.4%, 13.3%, and 12.9% respectively [15]. - Projected net profits for the same period are HKD 10.04 billion, HKD 12.57 billion, and HKD 14.83 billion, with corresponding growth rates of 32.8%, 25.2%, and 18.0% [15].

Investment Rating - The report maintains a "Buy" rating for the company, expecting significant price appreciation over the next 6-12 months [6]. Core Insights - The company is projected to achieve a revenue of 345.2 billion RMB in 2025, representing a 25% year-on-year growth, with a core net profit of 14.4 billion RMB, up 36% year-on-year [2]. - The strong revenue growth is driven by a robust new product cycle and optimization of product structure, with Q4 2025 revenue reaching 105.8 billion RMB, a 22% increase year-on-year and a 19% increase quarter-on-quarter [3]. - The company is expected to benefit from high profit elasticity from high-end vehicles, with the Zeekr 9X production ramping up and the Zeekr 8X set to launch in Q2 2026 [4]. Revenue and Profitability - The company achieved a total sales volume of 850,000 units in Q4 2025, a 24% increase year-on-year and a 12% increase quarter-on-quarter [3]. - The average selling price (ASP) per vehicle was 124,000 RMB, down 21,000 RMB year-on-year, attributed to the increased sales proportion of the Galaxy model [3]. - The gross profit margin for Q4 2025 was 16.9%, a decrease of 0.5 percentage points year-on-year, but an increase of 0.3 percentage points quarter-on-quarter [4]. Future Outlook - The company is expected to continue its strong growth trajectory, with projected net profits of 20.8 billion RMB, 24.8 billion RMB, and 28.2 billion RMB for 2026, 2027, and 2028 respectively [6]. - The company plans to expand its product lineup with new energy vehicles and hybrid models, which are anticipated to drive sales growth and enhance risk resilience [5]. - The export of new energy vehicles is expected to maintain high growth, with cumulative sales exceeding 120,000 units in the first two months of 2025 [5].

Investment Rating - The report maintains a "Buy" rating for Leap Motor, with a target valuation of HKD 103 billion, corresponding to an 18x P/E for 2026 and a 0.8x P/S for 2026, with a target price of HKD 72 [4][6]. Core Insights - Leap Motor is expected to achieve profitability in 2025, with a projected sales volume of 597,000 units, doubling sales for two consecutive years, and revenue reaching HKD 64.7 billion, a year-on-year increase of 56.1% [1][2]. - The company plans to maintain a sales target of 1 million units and a profit target of HKD 5 billion for 2026, supported by the launch of four new models from the A and D series [2][4]. - Leap Motor's overseas market expansion is progressing steadily, with 67,000 units exported in 2025, leading the Chinese new energy vehicle sector [3]. Summary by Sections Financial Performance - In Q4 2025, Leap Motor achieved a sales volume of 201,000 units, a 66% year-on-year increase, contributing to a total revenue of HKD 21 billion for the quarter [1]. - The gross profit margin for Q4 2025 reached 15%, with an annual gross margin improvement of 6.1 percentage points to 14.5% [1]. - The net profit attributable to shareholders for 2025 was HKD 540 million, marking the first annual profit for the company [1][4]. Sales and Product Strategy - The company will launch four new models in 2026, including A10 and D19, to ensure strong sales growth [2]. - Leap Motor's sales network has expanded to cover 295 cities with 950 sales stores and 526 service centers, aiming to enhance channel quality [2]. Market Expansion - Leap Motor's export strategy includes establishing approximately 900 sales and service points in various international markets, with significant growth expected in South America and Asia-Pacific [3]. - Local production initiatives are underway, with plans for a factory in Spain to begin production of the B10 model by October 2026 [3].